Galderma Acne Ingredient Rx-to-OTC Switch Headed For NDAC In April
This article was originally published in The Rose Sheet
Executive Summary
FDA schedules an April 15 NDAC meeting to consider whether data in Galderma's supplemental NDA support an acceptable risk/benefit profile for nonprescription use of adapalene gel 0.1.